AC Wolff, MEH Hammond, DG Hicks… - Journal of clinical …, 2013 - ascopubs.org
Purpose To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor …
S Vranic, B Teruya, S Repertinger, P Ulmer… - Cancer, 2011 - Wiley Online Library
BACKGROUND: The current study was performed to determine the impact of polysomy 17 on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ …
J Lehmann-Che, F Amira-Bouhidel, E Turpin… - British journal of …, 2011 - nature.com
Background: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status. PCR-based assays …
S Louzada, F Adega, R Chaves - PloS one, 2012 - journals.plos.org
Cancer cell lines have been shown to be reliable tools in genetic studies of breast cancer, and the characterization of these lines indicates that they are good models for studying the …
PP Advani, JA Crozier, EA Perez - Biomarkers in medicine, 2015 - Taylor & Francis
Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing …
Human ERBB2 is a proto-oncogene that codes for the erbB-2 epithelial growth factor receptor. In human breast cancer (HBC), erbB-2 protein overexpression has been …
X Pu, J Shi, Z Li, A Feng, Q Ye - Pathology-Research and Practice, 2015 - Elsevier
It has been proven that chromosome 17 centromere (CEP17) amplification causes misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ …
G Zoppoli, A Garuti, G Cirmena, LV di Cantogno… - Journal of Translational …, 2017 - Springer
Background Immunohistochemistry (IHC) and fluorescent-in situ hybridization (FISH) are standard methods to assess human epidermal growth factor receptor 2 (HER2) status in …
V Koudelakova, J Berkovcova, R Trojanec… - The Journal of Molecular …, 2015 - Elsevier
Administration of drugs targeting HER2 (official symbol ERBB2) is an important component of therapy for breast cancer patients with HER2 amplification/overexpression as determined …